Viewing Study NCT06388772



Ignite Creation Date: 2024-05-06 @ 8:27 PM
Last Modification Date: 2024-10-26 @ 3:28 PM
Study NCT ID: NCT06388772
Status: COMPLETED
Last Update Posted: 2024-04-29
First Post: 2024-04-25

Brief Title: Study to Assess PK Safety and Tolerability Early in Healthy Subjects
Sponsor: Changzhou Qianhong Bio-pharma Co Ltd
Organization: Changzhou Qianhong Bio-pharma Co Ltd

Study Overview

Official Title: Phase I Clinical Study of Tolerability Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses
Status: COMPLETED
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the safety tolerability and pharmacokinetics PK of QHRD106 early in Chinese healthy subjects with single doses
Detailed Description: Eight dose groups were initially set up The experimental groups were increased from low to high dose according to the principle of increasing dose and Placebo was added as the control group All the selected subjects in the experimental group were given the drug once

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None